How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?

被引：0
|
作者：
Zheng, Lucy [1 ]
Zheng, X. Long [1 ]
机构：
[1] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, 3901 Rainbow Blvd,Delp 5016, Kansas City, KS 66160 USA
来源：
ANNALS OF BLOOD | 2023年 / 8卷
关键词：
PLASMA-EXCHANGE; REFRACTORINESS; MORTALITY; ADAMTS13;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?
    Zheng, Lucy
    Zheng, X. Long
    ANNALS OF BLOOD, 2023, 8
  • [2] Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
    Scully, M.
    Cataland, S. R.
    Peyvandi, F.
    Coppo, P.
    Knobl, P.
    Hovinga, J. A. Kremer
    Metjian, A.
    de la Rubia, J.
    Pavenski, K.
    Callewaert, F.
    Biswas, D.
    De Winter, H.
    Zeldin, R. K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (04): : 335 - 346
  • [3] Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?
    Picod, Adrien
    Veyradier, Agnes
    Coppo, Paul
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (01) : 58 - 67
  • [4] Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura
    Reid, Justin H.
    Durant, Karin M.
    Chen, Sheh-Li
    Perissinotti, Anthony J.
    King, Richard
    Khoriaty, Rami
    Marini, Bernard L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (07) : 1695 - 1702
  • [5] Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment
    le Besnerais, Maelle
    Veyradier, Agnes
    Benhamou, Ygal
    Coppo, Paul
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (11) : 1127 - 1134
  • [6] Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
    Voelker, Linus A.
    Kaufeld, Jessica
    Balduin, Gesa
    Merkel, Lena
    Kuehne, Lucas
    Eichenauer, Dennis A.
    Osterholt, Thomas
    Haegele, Holger
    Kann, Martin
    Grundmann, Franziska
    Kolbrink, Benedikt
    Schulte, Kevin
    Gaeckler, Anja
    Kribben, Andreas
    Boss, Kristina
    Potthoff, Sebastian A.
    Rump, Lars C.
    Schmidt, Tilman
    Muehlfeld, Anja S.
    Schulmann, Karsten
    Hermann, Matthias
    Gaedeke, Jens
    Sauerland, Kristin
    Bramstedt, Joern
    Hinkel, Ulrich P.
    Miesbach, Wolfgang
    Bauer, Frederic
    Westhoff, Timm H.
    Bruck, Heike
    Buxhofer-Ausch, Veronika
    Mueller, Tobias J.
    Wendt, Ralph
    Harth, Ana
    Schreiber, Adrian
    Seelow, Evelyn
    Toelle, Markus
    Gohlisch, Christopher
    Bieringer, Markus
    Geuther, Gesa
    Jabs, Wolfram J.
    Fischereder, Michael
    von Bergwelt-Baildon, Anke
    Schoenermarck, Ulf
    Knoebl, Paul
    Menne, Jan
    Brinkkoetter, Paul T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2023, 21 (03) : 559 - 572
  • [7] Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura
    Poullin, P.
    Bornet, C.
    Veyradier, A.
    Coppo, P.
    DRUGS OF TODAY, 2019, 55 (06) : 367 - 376
  • [8] A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura
    Gomez-Segui, Ines
    Fernandez-Zarzoso, Miguel
    de la Rubia, Javier
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (11) : 1153 - 1164
  • [9] Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial)
    Estcourt, L. J.
    TRANSFUSION MEDICINE, 2019, 29 (03) : 146 - 148
  • [10] Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States
    Sullivan, Sean D.
    Chaturvedi, Shruti
    Gautam, Preety
    Arnaud, Alix
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2025, 31 (03): : 277 - 288
12345